Mesoblast (MESO) Price & Analysis

Compare

872 Followers

MESO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.00 - $22.00

Previous CloseN/A

Volume155.35K

Average Volume (3M)243.63K

Market Cap

$2.02B

Enterprise ValueN/A

Total Cash (Recent Filing)$38.03M

Total Debt (Recent Filing)$126.11M

Price to Earnings (P/E)―

Beta1.35

Next Earnings

Aug 27, 2025

EPS Estimate

-0.37

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding127,996,720

10 Day Avg. Volume109,537

30 Day Avg. Volume243,635

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$23.00

Price Target Upside41.54% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

FDA Approval PathwayFDA alignment on Mesoblast's approval pathway for Revascor in end-stage ischemic heart failure positions the company for potential approval.

Financial StabilityMesoblast is funded well into 2026, providing financial stability and allowing sustained development efforts.

Market OpportunityThe potential pricing for Ryoncil over $1.5M supports a significant market opportunity, validating the potential value of the GvHD market.

Bears Say

FDA Approval DependencyMesoblast's future prospects heavily depend on FDA approval for its products, which remains uncertain until finalized.

Regulatory ChallengesFDA's requirement for a confirmatory study targeting mortality in Class II–III patients may delay broader approval and commercialization.

Mesoblast News

Mesoblast downgraded to Hold from Buy at Jefferies

Jefferies analyst David Stanton downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.60, up...

30d ago

MESO

Mesoblast reports Q1 Ryoncil gross revenue $13.2M

Mesoblast (MESO) announced gross revenue from sales of Ryoncil through the first quarter post product launch. Ryoncil is...

1M ago

MESO

Mesoblast Announces Cessation of Securities and Capital Adjustments

Mesoblast ( ($MESO) ) has issued an update. On July 14, 2025, Mesoblast Limited announced several filings with...

1M ago

MESO

Buy Rating for Mesoblast: FDA Alignment and Promising Revascor Data Drive Optimism

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Mesoblast, with a...

1M ago

MESO

Mesoblast gives update on Revascor accelerated approval, Ryoncil label extension

Mesoblast (MESO) provided an update on continued momentum with FDA regarding both accelerated approval pathway for Revascor in...

2M ago

MESO

MESO Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Mesoblast (MESO) is scheduled to report 3rd quarter earnings on 05/28/2025. Regarding Q3 estimates, Wall Street analysts expect...

3M ago

MESO

Mesoblast gets years of orphan-drug exclusive approval from FDA for Ryoncil

Mesoblast (MESO) announced that it has received seven years of orphan-drug exclusive approval from FDA for Ryoncil for...

3M ago

MESO

Mesoblast extends payer coverage for Ryoncil to over 100M U.S. lives

The company states: “Mesoblast (MESO) announced that it has continued to expand coverage for Ryoncil, the first mesenchymal...

4M ago

MESO

Mesoblast Updates Securities Status with ASX

Mesoblast ( ($MESO) ) has provided an announcement. On April 14, 2025, Mesoblast Limited, a company involved in...

4M ago

MESO

Mesoblast Announces Director Securities Changes Following AGM Approval

The latest announcement is out from Mesoblast ( ($MESO) ). On April 8, 2025, Mesoblast Limited announced changes...

4M ago

MESO

Mesoblast announces it entered into NDRA with CMS DHHS for Ryoncil

Mesoblast (MESO) announced that it has entered into the Medicaid National Drug Rebate Agreement, NDRA, with the U.S....

5M ago

MESO

Mesoblast added to S&P/ASX 200 index

Mesoblast (MESO) announced its addition to the S&P Dow Jones Indices’ S&P/ASX 200 Index effective March 6, 2025...

5M ago

MESO

Mesoblast’s Earnings Call: RYONCIL Approval & Growth

Mesoblast (($MESO)) has held its Q2 earnings call. Read on for the main highlights of the call. Mesoblast’s...

6M ago

MESO

Buy Rating for Mesoblast Driven by Promising Market Position and Strong Financial Backing

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Mesoblast (MESO – Research Report) and keeping...

6M ago

MESO

MESO FAQ

What was Mesoblast Ltd’s price range in the past 12 months?

Mesoblast Ltd lowest stock price was $6.00 and its highest was $22.00 in the past 12 months.

What is Mesoblast Ltd’s market cap?

Mesoblast Ltd’s market cap is $2.02B.

When is Mesoblast Ltd’s upcoming earnings report date?

Mesoblast Ltd’s upcoming earnings report date is Aug 27, 2025 which is in 10 days.

How were Mesoblast Ltd’s earnings last quarter?

Currently, no data Available

Is Mesoblast Ltd overvalued?

According to Wall Street analysts Mesoblast Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mesoblast Ltd pay dividends?

Mesoblast Ltd does not currently pay dividends.

What is Mesoblast Ltd’s EPS estimate?

Mesoblast Ltd’s EPS estimate is -0.37.

How many shares outstanding does Mesoblast Ltd have?

Mesoblast Ltd has 127,996,720 shares outstanding.

What happened to Mesoblast Ltd’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Mesoblast Ltd?

Currently, no hedge funds are holding shares in MESO

Mesoblast Stock Smart Score

Neutral

Fundamentals

Return on Equity

-21.26%

Trailing 12-Months

Asset Growth

-2.53%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mesoblast Ltd

Mesoblast Limited is a global leader in regenerative medicine, specializing in the development of innovative allogeneic cellular medicines. The company operates primarily within the biotechnology sector, focusing on the research, development, and commercialization of cellular therapies. Mesoblast's core products are based on its proprietary mesenchymal lineage cell technology platform, which aims to address significant unmet medical needs across various therapeutic areas, including inflammatory diseases, cardiovascular diseases, and orthopedic disorders.

Mesoblast (MESO) Earnings & Revenues

Historic Earnings Reports

MESO Stock 12 Month Forecast

Average Price Target

$23.00

▲(41.54% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","18":"$18","31":"$31","11.5":"$11.5","24.5":"$24.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,11.5,18,24.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.12,13.495384615384616,14.87076923076923,16.246153846153845,17.621538461538464,18.99692307692308,20.372307692307693,21.74769230769231,23.123076923076923,24.49846153846154,25.873846153846156,27.24923076923077,28.62461538461539,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.12,12.956923076923076,13.793846153846154,14.63076923076923,15.467692307692307,16.304615384615385,17.14153846153846,17.978461538461538,18.815384615384616,19.652307692307694,20.48923076923077,21.326153846153844,22.163076923076922,{"y":23,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.12,12.418461538461537,12.716923076923075,13.015384615384615,13.313846153846153,13.612307692307692,13.91076923076923,14.209230769230768,14.507692307692308,14.806153846153846,15.104615384615384,15.403076923076924,15.701538461538462,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.78,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.72,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.14,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.94,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.38,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.12,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >